Cyclipostins, process for their preparation and use thereof

US6756402B2 · kind B2 · utility

Assignee

• Aventis Pharma Deutschland GmbH · DE

Inventors

• Laszlo Vertesy · Eppstein, DE
• Klaus Ehrlich · Rüsselsheim am Main, DE
• Michael Kurz · Neustadt, DE
• Joachim Wink · Rödermark, DE

Key dates

• Filing date: Jun 22, 2001
• Grant date: Jun 29, 2004
• Expiry date: Jun 22, 2021

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12R2001/465
• WIPO field: Biotechnology
• WIPO sector: Chemistry

Abstract

The invention relates to compounds of formula I in which R1, R2, E, X1, X2, and X3 have the meaning as described in the specification and claims, obtained by culturing Streptomyces species HAG 004107 (DSM 13381), and their physiologically tolerable salts and chemical equivalents. The invention furthermore relates to a process for the preparation of the cyclipostins, the microorganism HAG 004107 (DSM 13381), the use of the cyclipostins and their physiologically tolerable salts and chemical equivalents as pharmaceuticals, in particular as inhibitors of lipases, and pharmaceutical preparations which contain cyclipostin or a physiologically tolerable salt or equivalent thereof.